Black Rock Inc. Aerie Pharmaceuticals Inc Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $720,937 - $1.72 Million	113,177 Added 3.3%	3,544,947 $53.6 Million
Q2 2022 Aug 12, 2022	BUY	$4.95 - $9.16 $587,881 - $1.09 Million	118,764 Added 3.58%	3,431,770 $25.7 Million
Q1 2022 May 12, 2022	SELL	$5.64 - $9.8 $411,770 - $715,488	-73,009 Reduced 2.16%	3,313,006 $30.1 Million
Q4 2021 Feb 10, 2022	SELL	$7.02 - $13.33 $264,317 - $501,901	-37,652 Reduced 1.1%	3,386,015 $23.8 Million
Q3 2021 Nov 09, 2021	BUY	$11.32 - $16.63 $1.03 Million - $1.52 Million	91,258 Added 2.74%	3,423,667 $39 Million
Q2 2021 Aug 11, 2021	BUY	$15.16 - $18.97 $50.5 Million - $63.2 Million	3,332,409 New	3,332,409 $53.4 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.